Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
24
GKOS Quote, Financials, Valuation and Earnings
Last price:
$109.53
Seasonality move
:
-5.36%
Day range:
$105.37 - $109.34
52-week range:
$73.16 - $161.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.88x
P/B ratio:
7.97x
Volume:
498.1K
Avg. volume:
811.5K
1-year change:
-25.69%
Market cap:
$6.1B
Revenue:
$383.5M
EPS (TTM):
-$1.55
Analysts' Opinion
-
Consensus RatingGlaukos Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $132.71, Glaukos Corp. has an estimated upside of 24.33% from its current price of $106.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $72.00 representing 32.55% downside risk from its current price of $106.74.
Fair Value
-
According to the consensus of 12 analysts, Glaukos Corp. has 24.33% upside to fair value with a price target of $132.71 per share.
GKOS vs. S&P 500
-
Over the past 5 trading days, Glaukos Corp. has underperformed the S&P 500 by -4.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Glaukos Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Glaukos Corp. has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Glaukos Corp. reported revenues of $133.5M.
Earnings Growth
-
Glaukos Corp. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Glaukos Corp. reported earnings per share of -$0.28.
Enterprise value:
6B
EV / Invested capital:
--
Price / LTM sales:
12.88x
EV / EBIT:
--
EV / Revenue:
12.69x
PEG ratio (5yr expected):
-31.08x
EV / Free cash flow:
-215.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$361.1M
Return On Assets:
-8.91%
Net Income Margin (TTM):
-18.65%
Return On Equity:
-11.73%
Return On Invested Capital:
-10.16%
Operating Margin:
-12.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $303.6M | $360.3M | $469.8M | $96.7M | $133.5M | |
| Gross Profit | $235.2M | $281.6M | $361.1M | $74.1M | $104.7M | |
| Operating Income | -$114.5M | -$109.9M | -$88.4M | -$24.7M | -$16.4M | |
| EBITDA | -$77M | -$73.4M | -$46.3M | -$15.7M | -$6.2M | |
| Diluted EPS | -$2.69 | -$2.96 | -$1.55 | -$0.39 | -$0.28 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $501.8M | $448.8M | $399.5M | $397.3M | $454.8M | |
| Total Assets | $1.1B | $1B | $948.6M | $926.5M | $999.4M | |
| Current Liabilities | $63.5M | $60.6M | $67.1M | $71.7M | $87.5M | |
| Total Liabilities | $463.1M | $459.9M | $471M | $258M | $229.8M | |
| Total Equity | $601M | $548.6M | $477.7M | $668.5M | $769.5M | |
| Total Debt | $382.4M | $382.5M | $383.8M | $157.1M | $104.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$51.2M | -$72.5M | -$21.1M | -$9.6M | -$10.1M | |
| Cash From Investing | $43.7M | $23.1M | -$49.9M | $30.6M | -$4M | |
| Cash From Financing | $8.3M | $38.7M | $69.6M | $9.7M | $5.3M | |
| Free Cash Flow | -$75.5M | -$81.3M | -$27.6M | -$11M | -$11.7M | |
GKOS
Sector
Market Cap
$6.1B
$24M
Price % of 52-Week High
65.98%
48.22%
Dividend Yield
0%
0%
Shareholder Yield
-0.38%
-1.63%
1-Year Price Total Return
-25.69%
-22.68%
Beta (5-Year)
0.705
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$112.62
200-day SMA
Buy
Level
$97.15
Bollinger Bands (100)
Buy
Level
85.31 - 115.59
Chaikin Money Flow
Buy
Level
45.2M
20-day SMA
Sell
Level
$117.60
Relative Strength Index (RSI14)
Sell
Level
37.69
ADX Line
Sell
Level
19.73
Williams %R
Buy
Level
-94.1628
50-day SMA
Sell
Level
$114.06
MACD (12, 26)
Sell
Level
-0.97
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
64.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (18.3143)
Sell
CA Score
(Annual)
Level (-0.3299)
Buy
Beneish M-Score
(Annual)
Level (-2.2747)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.2883)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
Stock Forecast FAQ
In the current month, GKOS has received 11 Buy ratings 0 Hold ratings, and 1 Sell ratings. The GKOS average analyst price target in the past 3 months is $132.71.
-
Where Will Glaukos Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Glaukos Corp. share price will rise to $132.71 per share over the next 12 months.
-
What Do Analysts Say About Glaukos Corp.?
Analysts are divided on their view about Glaukos Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Glaukos Corp. is a Sell and believe this share price will drop from its current level to $72.00.
-
What Is Glaukos Corp.'s Price Target?
The price target for Glaukos Corp. over the next 1-year time period is forecast to be $132.71 according to 12 Wall Street analysts, 11 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GKOS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Glaukos Corp. is a Buy. 11 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GKOS?
You can purchase shares of Glaukos Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Glaukos Corp. shares.
-
What Is The Glaukos Corp. Share Price Today?
Glaukos Corp. was last trading at $109.53 per share. This represents the most recent stock quote for Glaukos Corp.. Yesterday, Glaukos Corp. closed at $106.74 per share.
-
How To Buy Glaukos Corp. Stock Online?
In order to purchase Glaukos Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GKOS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GKOS
Sector
P/E ratio
--
23.16x
PEG ratio
-31.08x
-0.01x
P/B ratio
7.97x
1.73x
Price / LTM sales
12.88x
1.50x
Growth Metrics
GKOS
Sector
Revenue growth
38.14%
3.24%
Earnings growth
27.3%
11.06%
Revenue (5-year growth)
10.11%
6.28%
Earnings forecast
-$0.20
-$0.19
Profitability
GKOS
Sector
Profitability FY 2024
$287.1M
$2.7M
Return on invested capital
-10.16%
-33.62%
Return on assets
-8.91%
-29.68%
Return on equity
-11.73%
-39.33%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Jan
28
Balance Sheet
GKOS
Sector
Total cash
$273.7M
$25.1M
Short term investments
$149.3M
$23.9M
Total assets
$1B
$72.8M
Long term debt
$104.3M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 15.9% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 0.31% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 2.47% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
